Literature DB >> 6125184

Influence of intrinsic sympathomimetic activity (ISA) during beta-adrenoceptor blockade in asthmatics.

P Dorow.   

Abstract

1 Ten patients suffering from extrinsic bronchial asthma were examined. 2 In the pretreatment period, the histamine concentration required to produce a 20% decrease of forced expiratory volume in one second (FEV1) was 7.71 mg/ml. 3 Histamine provocation was repeated 2 h after administration of placebo, propranolol 40 mg, pindolol 5 mg or metoprolol 50 mg. After pindolol and metoprolol the histamine concentrations were slightly, but not significantly, lower than after placebo. After propranolol only 3.16 mg/ml histamine was necessary to reduce FEV1 by 20%. 4 This indicates that in equipotent cardiac beta-adrenoceptor blocking doses, in contrast to propranolol, neither pindolol nor metoprolol increased sensitivity to the bronchoconstrictor effects of inhaled histamine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125184      PMCID: PMC1402139          DOI: 10.1111/j.1365-2125.1982.tb01936.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  1 in total

1.  Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.

Authors:  R E Ruffin; P A Frith; R C Anderton; C R Kumana; M T Newhouse; F E Hargreave
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

  1 in total
  3 in total

Review 1.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

2.  Comparative study of the respiratory effects of two beta 1-selective blocking agents atenolol and bevantolol in asthmatic patients.

Authors:  F Philip-Joet; A Saadjian; B Bruguerolle; A Arnaud
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.

Authors:  P Dorow; W Schiess
Journal:  Klin Wochenschr       Date:  1986-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.